Too much of a good thing?

How to successfully deprescribe

Camille Gagnon, PharmD
Clinical Pharmacist, MDCM-GMF Clinic
Assistant Director, Canadian Deprescribing Network
Presenter Disclosure

• Faculty:
  – Camille Gagnon, PharmD

• Relationships with commercial interests:
  – None, either related or unrelated to this presentation

• Other
  – Assistant-Director, CaDeN
Learning Objectives

1. Explain the risks of over-medication and the benefits of deprescribing to patients and caregivers.
2. Develop an approach to deprescribing common high-risk medications in older adults across the care continuum.
3. Manage and foster safe medication use in older adults.
Is medication use good or bad?

- **Good**
  - Provides symptomatic relief
  - Treats conditions to reduce morbidity
  - Reduces mortality when used correctly
  - Helps with patient expectations
  - Makes the prescriber feel like they are “helping”
Why is there an issue?

- High drug utilization
  - More chronic diseases
  - Use of more preventative therapies
  - Self-medication with OTC products
  - Use of increasing numbers of complementary and alternative medications
Why? Because longer life expectancy, more chronic conditions…

In Canada:

• 1-in-4 seniors have $\geq 3$ chronic conditions

• Persons with 1-2 chronic conditions take 3-4 prescription medications on average

• Persons with 3 or more conditions take 6 different medications on average

• ER visits and hospitalizations result in new medications being added

### Top 10 medications in seniors - Canada

<table>
<thead>
<tr>
<th>Rank</th>
<th>Drug class</th>
<th>Rate of use</th>
<th>Rate of chronic use</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>HMG-CoA reductase inhibitors</td>
<td>48.4%</td>
<td>43.5%</td>
</tr>
<tr>
<td>2</td>
<td>Proton pump inhibitors</td>
<td>32.1%</td>
<td>23.5%</td>
</tr>
<tr>
<td>3</td>
<td>ACE inhibitors</td>
<td>24.5%</td>
<td>21.1%</td>
</tr>
<tr>
<td>4</td>
<td>Beta-blocking agents, selective</td>
<td>23.5%</td>
<td>20.6%</td>
</tr>
<tr>
<td>5</td>
<td>Dihydropyridine derivatives</td>
<td>21.9%</td>
<td>18.8%</td>
</tr>
<tr>
<td>6</td>
<td>Thyroid hormones</td>
<td>19.1%</td>
<td>17.9%</td>
</tr>
<tr>
<td>7</td>
<td>Angiotensin II antagonists</td>
<td>15.7%</td>
<td>13.8%</td>
</tr>
<tr>
<td>8</td>
<td>Natural opium alkaloids</td>
<td>15.1%</td>
<td>2.5%</td>
</tr>
<tr>
<td>9</td>
<td>Biguanides</td>
<td>14.9%</td>
<td>12.9%</td>
</tr>
<tr>
<td>10</td>
<td>Benzodiazepine derivatives</td>
<td>12.9%</td>
<td>6.1%</td>
</tr>
</tbody>
</table>

Canadian Institute for Health Information. Drug Use Among Seniors in Canada 2016, (2018)
Problems with polypharmacy

1. Side effects
2. Drug interactions
3. Hospitalizations
4. Costs

More medication leads to more...
Medications and Falls

Which medications increase the risk of falls?

- Diuretics: 7% increased risk
- Opioid painkillers: 10% increased risk
- Anti-inflammatory drugs: 21% increased risk
- Blood pressure medication: 24% increased risk
- Sleeping pills (benzodiazepines): 47-57% increased risk
- Antipsychotics: 59% increased risk
- Antidepressants: 68% increased risk

de Jong et al. 2013
& Huang et al. 2012
Risk of hospitalization because of side effects increases with # of meds

<table>
<thead>
<tr>
<th>Number of medications</th>
<th>Proportion of seniors hospitalized because of a medication side effect (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>0.25 (95% CI 0.17-0.32)</td>
</tr>
<tr>
<td>5-9</td>
<td>1.00 (95% CI 0.85-1.15)</td>
</tr>
<tr>
<td>10-14</td>
<td>2.00 (95% CI 1.85-2.15)</td>
</tr>
<tr>
<td>15+</td>
<td>6.40 (95% CI 5.67-7.13)</td>
</tr>
</tbody>
</table>

Potentially inappropriate medications

- Also identified as “PIM”

- A medication or medication class where harm outweighs the benefit, and there are safer alternatives available.
  - Include both drug and non-drug alternatives
The cost of potentially inappropriate medication

$419 million
Canadians spend $419M per year on potentially harmful prescription medications. This does not include hospital costs.

$1.4 billion
Canadians spend $1.4B per year in health care costs to treat harmful effects from medications, including fainting, falls, fractures and hospitalizations.

Deprescribing means reducing or stopping medications that may not be beneficial or may be causing harm. The goal of deprescribing is to maintain or improve quality of life.

Deprescribing involves patients, caregivers, healthcare providers and policy makers.
Self-evaluation

On a scale of 0 to 10, how confident are you about your deprescribing skills?

0  Not at all

10 Extremely
Here is Mrs S, aged 74

Active medical conditions

- DM II
- HTN
- OA (knee)
- Depression (2013)
- Urinary incontinence
- Itchy skin (especially after showering)
- Fell last week while going to the washroom (at night)
Mrs S’s medication list

- Metformin 850mg po tid
- Lorazepam 1mg po hs
- Perindopril-erbumine 8mg po od
- Naproxen EC 500mg po BID regular
- Dexilant 60mg po od
- Rosuvastatine 10mg po od
- Glyburide 5mg po BID
- Hydroxyzine 25mg po hs PRN *(for pruritus)*
- Citalopram 20mg po od
- Carbocal D 400 po BID
- Oxybutynin 5mg po BID
How many medications would you consider deprescribing?

- Metformin 850mg po tid
- Lorazepam 1mg po hs
- Perindopril-erbumine 8mg po od
- Naproxen EC 500mg po BID regular
- Dexilant 60mg po od
- Rosuvastatine 10mg po od
- Glyburide 5mg po BID
- Hydroxyzine 25mg po hs PRN *(for pruritus)*
- Citalopram 20mg po od
- Carbocal D 400 po BID
- Oxybutynin 5mg po BID
How many prescribing cascades or interactions?

- Metformin 850mg po tid
- Lorazepam 1mg po hs
- Perindopril-erbumine 8mg po od
- Naproxen EC 500mg po BID regular
- Dexilant 60mg po od
- Rosuvastatine 10mg po od
- Glyburide 5mg po BID
- Hydroxyzine 25mg po hs PRN *(for pruritus)*
- Citalopram 20mg po od
- Carbocal D 400 po BID
- Oxybutynin 5mg po BID
3 easy steps to become a deprescriber

1. **IDENTIFY** which drugs to deprescribe

2. Use **EVIDENCE-BASED** deprescribing algorithms

3. **ENGAGE** your patients and other health care providers in the deprescribing process using effective communication tools and techniques
Step 1: Identify which drugs to deprescribe - potentially inappropriate medications

- Various tools are available:
  - Implicit (Judgement based)
    - Medication Appropriateness Index
  - Explicit (Criterion based)
    - Beers list (used by CIHI)
    - STOPP / START
    - Drug Burden Index (*Hilmer SN et al 2007 Arch Int Med*)
Medication Appropriateness Index

Questions:
- What is indication?
- Recognized effectiveness for condition?
- Correct dosage/duration
- Correct & practical instructions?
- Significant ADR’s & drug-disease interactions?
- Duplication?
- Cost?

AGS Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults (2015) – 53 drug classes

**Benzodiazepines**
- Temazepam
- Oxazepam
- Lorazepam
- Alprazolam
- Clonazepam
- Diazepam
- Flurazepam
- Clorazepate
- All antipsychotics

**Non-benzodiazepine sedative-hypnotics**
- Zolpidem
- Zopiclone
- Zaleplon

**Sulfonylurea oral hypoglycemics**
- Glyburide
- Glipizide
- Chlorpropamide

**Tricyclic antidepressants**
- Amitriptyline
- Nortriptyline
- Imipramine

**1st generation antihistamines**
- Hydroxyzine
- Diphenhydramine

**Cardiovascular agents**
- Amiodarone
- Digoxin > 0.125 mg/day

---

http://www.americangeriatrics.org/health_care_professionals/clinical_practice/clinical_guidelines_recommendations/2015
STO P P / S TA RT tool (2015)

• Screening Tool of Older Persons Prescriptions/
Screening Tool to Alert to Right Treatment

• Screening tool for patients 65 and over

• 114 criteria in last version
  – 80 STOPP
    • Long-term use of NSAID (> 3 months) for relief of mild joint pain in osteoarthritis
    • Proton pump inhibitor at treatment dose for peptic ulcer disease at full therapeutic
dosage for > 8 weeks
  
  – 34 START
    • Calcium supplement and bisphosphonate in patients at high risk of osteoporosis due
to long term treatment with steroids
Drug Burden Index (DBI)

• Anticholinergic activity: calculates cumulative exposure for a given patient
  – Associated with a reduced function, falls, higher frailty score, a higher utilization of health care resources and in some studies, with an increased risk of mortality
Tell your neighbour where you want to start and what your 6-month plan is

- Metformin 850mg tid
- Lorazepam 1mg po hs
- Perindopril-erbumine 8mg po od
- Naproxen EC 500mg po BID regular
- Dexilant 60mg po od
- Rosuvastatine 10mg po od
- Glyburide 5mg po BID
- Hydroxyzine 25mg po hs PRN (for pruritus)
- Citalopram 20mg po od
- Carbocal D 400 po BID
- Oxybutynin 5mg po BID
What to do first?

• Decide what should be tapered or stopped
• Stop the easy ones (no longer needed, have long half-lives, don’t cause withdrawal symptoms)
  – Oxybutynin
• Make a schedule for those that need to be **tapered:**
  – Beta-blockers, benzodiazepines, proton-pump inhibitors, diuretics, narcotics, anticonvulsants
• **Follow an evidence-based algorithm**
Step 2 : Use EVIDENCE-BASED deprescribing algorithms
Choose all that apply

An evidence-based deprescribing algorithm exists for:

1) Proton pump inhibitors
2) Antipsychotics
3) Benzodiazepine receptor agonists
4) Antihyperglycemic agents
Choose all that apply

I am familiar with the following deprescribing tools and resources:

1) EMPOWER brochures for patients
2) The MedStopper website
3) The deprescribing.org and deprescribingnetwork.ca websites
4) Sleepwell.ca
5) None of the above
EMPOWER brochures

www.deprescribingnetwork.ca
Tapering sedative-hypnotic medications

**TAPERING-OFF PROGRAM**

We recommend that you follow this schedule under the supervision of your doctor, nurse or pharmacist.

<table>
<thead>
<tr>
<th>WEEKS</th>
<th>MO</th>
<th>TU</th>
<th>WE</th>
<th>TH</th>
<th>FR</th>
<th>SA</th>
<th>SU</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 and 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 and 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 and 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 and 8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 and 10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 and 12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13 and 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15 and 16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 and 18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**EXPLANATIONS**

- Full dose
- Half dose
- Quarter of a dose
- No dose
Tackling benzos….TRUE or FALSE?

① Night-time consumption of benzodiazepines does not increase the risk of motor vehicle accidents

② Only the long-acting benzodiazepines are associated with memory impairment, falls and fractures in the elderly

③ Episodic use of benzodiazepines incurs less harm than chronic use

④ The Z-drugs (zopiclone, zolpidem) confer the same risk of fractures as classic benzodiazepines, so are not a safer alternative for older people.
What does research evidence tell us about patients not wanting to taper benzos?
EMPOWER = “Eliminating medications through patient ownership of end results”

30 community pharmacies around Montreal 2,716 chronic benzo users 65+, 303 participants, benzo users 3 months+, aged 65 years and older no dementia, not on antipsychotics

WAIT-LIST CONTROL 155 participants
INTERVENTION 148 participants

Randomization

5 % complete discontinuation
27 % complete discontinuation

6-month follow-up

EMPOWER = “Eliminating medications through patient ownership of end results”

30 community pharmacies around Montreal 2,716 chronic benzo users 65+, 303 participants, benzo users 3 months+, aged 65 years and older no dementia, not on antipsychotics

Prevalence difference = 23 %
(95 % CI 14 %-32 %)
NNT = 4 for complete discontinuation
NNT = 3 for discontinuation or dose reduction

5 % complete discontinuation
27 % complete discontinuation
6-month follow-up

Step 3 : Engage your patients and other health care providers in the deprescribing process
Role Play:
Talk to the patient next to you (Mrs. S.) about getting off the sleeping pill she has been taking for 30 years.
Which way did you start the deprescribing conversation?

① Direct deprescribing method: “I see you are taking a lot of pills, I want to discuss getting you off some of them”

71% of Canadian seniors are willing to stop a medication if their doctor says it is possible. (Sirois et al., 2016)
Which way did you start the deprescribing conversation?

① Direct deprescribing method: “I see you are taking a lot of pills, I want to discuss getting you off some of them”

② Indirect method: “How’s your sleep?....There is some new research about sleeping pills that I want to discuss with you. I’d like to try switching you to non-drug therapy”

③ Emotional method “About your memory problems, falls, etc….I’m worried that…”

④ Use the EMPOWER brochure: “Read this for next time”
“But what can I take instead?”

I’m going to prescribe this because I don’t have time to explain why all you really need is fresh air.
What about other sleeping pills?

- Neither quetiapine nor trazodone are indicated for sleep
  - Off-label prescribing
  - Associated with adverse effects (falls, fractures)

- Over the counter sleep remedies’ (diphenhydramine/acetaminophen (eg Tylenol PM®) and dimenhydrinate (eg Gravol®)) active ingredient is 1st generation antihistamines – with equally powerful cognitive effects

- Melatonin
  - reduced sleep latency by 9 minutes [95% CI 4-10]
  - increased total sleep time by 8 minutes [95% CI 1 – 15]
  - Side effects: headaches, confusion, irritability, depression and stomach upset
  - No significant effect on the success of tapering benzos

Tips for tapering benzos:

Go slow! Reducing by 25% every 2 weeks is too fast. Prepare your patient for withdrawal symptoms.
Handling withdrawal symptoms

• Common withdrawal symptoms include:
  – Sleeplessness, anxiety/irritability, nightmares, depression, depersonalisation, hallucinations, irritable bowel symptoms, muscle, tension
  – Worse in the last ¾ of the taper
  – NO NEED to schedule a follow up visit until taper is finished

• Should the patient be “updosed” during withdrawal?
  – NO. This will only exacerbate withdrawal symptoms.
  – Be firm. Be tough. ‘I know you can do it’
  – If patients hit a "sticky patch" during the course of withdrawal, staying on the same dose for a longer period (not more than a few weeks) before resuming the withdrawal schedule allows them to overcome this obstacle. This is the “grit your teeth” and carry on approach.

• The use of SSRIs for anxiety, unmasking depression?

The role of the sleep diary

<table>
<thead>
<tr>
<th>Example</th>
<th>Monday</th>
<th>Tuesday</th>
<th>Wed</th>
<th>Thursday</th>
<th>Friday</th>
<th>Saturday</th>
<th>Sunday</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Yesterday, I took a nap from ____ to ____ (Record all naps.)</td>
<td>1:50 pm to 2:30 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Yesterday, I took ____ mg of medication and/or ____ oz of alcohol to help me sleep.</td>
<td>Immovane 3.75 mg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. (a) I went to bed at ____ h and (b) I turned off the lights at ____ h.</td>
<td>10:45 pm 11:15 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. After turning off the lights, I fell asleep after ____ minutes.</td>
<td>60 min</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. I woke up ____ times during the night. (Indicate the number of times)</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. I stayed awake ____ min each time. (Indicate how many minutes you stayed awake each time.)</td>
<td>10, 5, 45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. This morning, I woke up at ____ h. (Record the last time you woke up.)</td>
<td>6:20 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. This morning I got out of bed at ____ h.</td>
<td>6:40 am</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. When I got up, I felt: 1 = exhausted, 2 = tired, 3 = average, 4 = rested, 5 = very well rested</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Overall, my sleep last night was: 1=very restless, 2=restless, 3=average, 4=deep, 5=very deep</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Sleep efficiency = \( \frac{\text{Total time asleep}}{\text{Total time in bed}} \)
What is cognitive behavioural therapy for insomnia (CBT-i)?

- More than sleep hygiene
  - Don’t drink caffeinated beverages before bed
  - Don’t exercise before bed
  - Use relaxation tapes, warm bath, to de-stress before bed
- 6-12 individual or group sessions that:
  - Combat myths: e.g. unrealistic to expect to sleep 8-10 hours per night
  - Sleep restrict: Fixed bedtime (11 p.m.) and wake time (6 a.m.)
  - Introduce stimulus control: If you are lying in bed and not sleeping – get up and go write down your worries, read a book in a chair until you feel tired, above all don’t panic
  - Maximize sleep efficiency = time asleep/total time in bed, aim for >85%
- Achieves a clinical response in 70-80% of patients
  - Clinical remission in 40%
  - NO SIDE EFFECTS
## Effectiveness of CBTi versus sedative-hypnotics

**CBTi**

- **Sleep onset latency**
  - Post-treatment -23 minutes (-37 to -10)
  - 12 months -17 (-30 to -4)

- **Total wake time at night**
  - Post -68 minutes (-96 to -40)
  - 12 months -31 (-58 to -4)

- **Sleep efficiency**
  - Post +10% (5% to 15%)
  - 12 months +5% (0.5% to 10%)

**Benzos & Z-drugs**

- **Sleep onset latency**
  - -22 minutes (95% CI 11-33 minutes), compared to placebo

- **NNT to improve sleep quality = 13**

- **Total wake time at night**
  - Post -25 minutes (-38 to -13) vs placebo

- **Decrease in total number of awakenings**
  - 0.63 (-0.48 to -0.77) vs placebo

---

Glass et al. Meta-analysis. *BMJ* 2005  
Huedo-Medina et al. Meta-analysis 2012
How to refer your patient for CBTi

- Download and distribute a CBT brochure
- Ask your patient to download an app
- Set up group coaching in your practice
- Refer to a specialist

http://mysleepwell.ca/
Deprescribing is a team sport

- **Physiotherapist** – help with pelvic floor muscle exercises, assist with exercise program and fall prevention
- **Social Worker** – help with anxiety, depression, isolation affecting sleep and depression
- **Occupational therapist** – help with mobility aids if needed
- **Dietician** – help to use dietary approaches for GERD, weight loss if needed
- **Nurse** – monitor impact of medication changes, provide education re: nonpharmacologic approaches (CBTi, GERD management, heart failure self-management)
- **Psychologist** – conduct group CBT sessions for insomnia or anxiety, memory testing
- **Pharmacist** – help to identify drug-related problems, develop plans for medication changes, tapering and glucose monitoring if required
Post-test

On a scale of 0 to 10, how confident are you about your deprescribing skills?

0 Not at all

10 Extremely
Embrace your inner deprescriber

• Deprescribe at least 1 drug per day
• Track your stats/develop a quality improvement project
• Commit to launching group CBTi sessions for your practice
• Download the EMPOWER brochures and algorithms!
• Subscribe to the Canadian Deprescribing Newsletter (deprescribingnetwork.ca)
Learn more about the Canadian Deprescribing Network and stay in touch.

Subscribe to our newsletter!

Website: deprescribingnetwork.ca
Email: info@deprescribingnetwork.ca
Twitter: @DeprescribeNet
Facebook: @deprescribingnetwork